News & Events



New BD BACTEC™ FX Blood Culture Instrument with the BD EpiCenter™ Operating System can Facilitate Fast and Effective Clinical Decisions for Patients with Bacterial Infections


Sparks, MD USA  - BD Diagnostics, a segment of BD, today announced the U.S. launch of the BD BACTEC™ FX Blood Culture System for the detection of bloodstream infections. This new system improves clinical decision-making and laboratory workflow by markedly improving blood culturing practices with real-time, remotely accessible, actionable results that can enhance patient care.

"The new BD BACTEC FX System responds to customer requests for an efficient blood culture workflow process by reducing hands-on time and enhancing blood culture observation in and out of the microbiology lab," said David Panneton, Vice President WW Marketing, BD Diagnostics – Diagnostic Systems. "It is the result of 40 years of blood culturing expertise and customer interaction, with more than 10,000 blood culture instruments installed worldwide."

The system enables remote observation of blood culture data from outside the microbiology department through integration with the BD EpiCenter™ Microbiology Data Management System. This innovative capability allows clinician access to laboratory results during any shift and provides a visible and audible alarm on the remote BD EpiCenter™ client or on an existing computer monitor in a more highly occupied area of the lab. All of the information is available by fax, e-mail, mobile phone text messaging or beeper to any off-site healthcare professional. Lab personnel no longer need to interrupt evening or midnight workflow to repeatedly check the microbiology department for positive blood cultures.

By providing data access at the same remote computer that provides the alarm, the system facilitates immediate decision-making. With the information provided, clinicians can initiate appropriate next steps to diagnose the infection, such as performing a Gram stain, subculture, or direct identification of methicillin-susceptible or methicillin-resistant Staphylococcus aureus with the BD GeneOhm™ Staph SR assay.These steps could lead to earlier appropriate clinical decisions for effective antimicrobial interventions.

Multi-source data integration provides for comprehensive reporting capabilities across all BACTEC FX and BACTEC 9000 blood culture instruments, eliminating the need for manual report consolidation on more than five instruments. Data from up to numerous BACTEC FX instruments can be consolidated into one reporting system with the BD EpiCenter system.

The BD BACTEC FX system maintains the proven high performance and instrument reliability of its predecessor, the BD BACTEC™ 9000 System. It retains the fluorescent technology representing excellence in blood culture isolate recovery, along with exceptional instrument and media performance. The BACTEC FX System has a compact and versatile system design, It offers a 200-vial benchtop unit or a full 400-vial stack that includes an embedded, centralized computer - all in a highly compact 24-inch linear space which represents the smallest and most reliable design available. For more information, visit: www.bd.com/ds.

About BD
BD, a leading global medical technology company that manufactures and sells medical devices, instrument systems and reagents, is dedicated to improving people’s health throughout the world. BD is focused on improving drug therapy, enhancing the quality and speed of diagnosing infectious diseases, and advancing research and discovery of new drugs and vaccines. The Company’s capabilities are instrumental in combating many of the world’s most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 28,000 people in approximately 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, industry and the general public. For more information, please visit www.bd.com.




This press release may contain certain forward-looking statements (as defined under Federal securities laws) regarding BD\'s performance, including future revenues, products and income, or events or developments that BD expects to occur or anticipates occurring in the future. All such statements are based upon current expectations of BD and involve a number of business risks and uncertainties. Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement. Factors that could cause actual results to vary materially from any forward-looking statement include, but are not limited to: competitive factors; pricing and market share pressures; changes in interest or foreign currency exchange rates; difficulties inherent in product development and delays in product introductions; changes in regional, national or foreign economic conditions; increases in energy costs; fluctuations in costs and availability of raw materials and in BD\'s ability to maintain favorable supplier arrangements and relationships; and changes in healthcare or other governmental regulation; issuance of new or revised accounting standards, as well as other factors discussed in this press release and in BD\'s filings with the Securities and Exchange Commission. We do not intend to update any forward-looking statements to reflect events or circumstances after the date hereof except as required by applicable laws or regulations.